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www.jacctctabstracts2014.com SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PMResults: Pre-procedural EF was not different between two groups (34.3  5.9 vs. 32.4
 6.2%, P¼0.10). The CABG group included more patients with triple-vesseldisease
(P< 0.001) and the PCI group included more patients with presenting with myocardial
infarction (MI) (P¼0.002). At 2 years, death occurred in 7 (17.1%) of the PCI group
and 27 (15.7%) of the CABG group (P¼0.73). The composite of death, MI or stroke
occurred in 8 (19.5%) of the PCI group and 30 (17.4%) of the CABG group (P¼0.63).
The rates of target-vessel revascularization were signiﬁcantly higher in the PCI group
(4.9% vs. 0%, P¼0.003). After adjustment for the baseline characteristics, hazard ratio
was 0.94 (95% CI, 0.39w2.23; P¼0.88) for death; 0.99 (95% CI, 0.44w2.23;
P¼0.98) for the death, MI, or stroke; 186.6 (95% CI, contain 0; P¼0.58) for target-
vessel revascularization.
Conclusions: In patients with ULMCA disease and severe LVD, PCI and CABG
showed similar clinical outcomes at 2 year follow-up.
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Background: Percutaneous coronary intervention (PCI) for unprotected left main
trunk (ULMT), especially with single stent strategy, has favorable outcome with
advent of drug eluting stent (DES). Direct comparison of the outcome between PCI
with single stent strategy for ULMT bifurcation lesion and left anterior descending
artery (LAD) is lacking. The aim of this study is to testify the long-term feasibility of
PCI for ULMT bifurcation lesion with single stent strategy by comparison with LAD
lesion.
Methods:We investigated retrospectively 105 consecutive patients (mean age: 69.3
years old, female: 21.0% and diabetes mellitus: 38.1%) who were treated by siro-
limus eluting stent (SES) implantation with single stent strategy for ULMT bifur-
cation disease from August 2004 to December 2010 in our center. We compared
them with a matched group of 105 patients who underwent SES implantation for
LAD lesion with the same strategy. Matching criteria was identical age, gender and
presence of diabetes mellitus. All the cases were done with intravascular ultrasound
guidance. We assessed occurrence of MACE (a composite of cardiac death, non-
fatal acute myocardial infarction (AMI) and target lesion revascularization (TLR)),
cardiac death, AMI, stent thrombosis and TLR. Mean follow-up period was
65.328.4 months.
Results: There were no statistical differences in MACE and other endpoints between
the two groups (Figure). A favorable trend for ULMT lesion was shown in MACE
(p¼0.09).Conclusions: DES implantation with single stent strategy for ULMT bifurcation
lesion provides as feasible long-term outcome as for LAD lesion.JACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/CoTCT-229
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Background: Clinical outcomes after treatment of ostial/midshaft lesions in unpro-
tected left main coronary artery (ULMCA) with ﬁrst generation drug-eluting stents
(DES) have been found to be favorable. However, to date, data regarding new gen-
eration DES for these lesion subsets have not been reported. The aim of this study was
to compare the clinical outcomes following ULMCA percutaneous coronary inter-
vention (PCI) of ostial/midshaft lesions with ﬁrst versus new generation DES.
Methods: A total of 219 patients from the Milan New-Tokyo (MITO) registry with
ostial/midshaft lesions in ULMCA treated with ﬁrst (n¼139) or new generation DES
(n¼80) were analyzed.
Results: The ﬁrst generation DES group had more males (78.4% vs. 63.8%,
p¼0.026). There was a higher prevalence of IVUS use (35.2% vs. 50.0%, p¼0.032)
and post-dilation (70.5% vs. 93.8%, p < 0.001) with larger maximum balloon
diameter (3.810.45 vs. 4.080.44, p < 0.001) in the new generation DES group. At
a median follow-up period of 730 days, there were no signiﬁcant differences in the
propensity-score adjusted analyses, for major adverse cardiac events (MACE) deﬁned
as composite endpoint of all-cause death, myocardial infarction and target vessel
revascularization (HR [new vs. ﬁrst generation DES]: 1.22; 95% CI: 0.64 to 2.31;
p¼0.549). Of note, target lesion revascularization rates at 2-years were only 0.9% and
2.7%, for ﬁrst and new generation DES groups, respectively (p¼0.339). On multi-
variable analysis, SYNTAX score (HR: 1.06; 95% CI: 1.02-1.11, p¼0.006) and
EuroSCORE (HR: 1.14; 95% CI: 1.00-1.31, p¼0.051) were independent predictors
for MACE.
Conclusions: This study suggests that new generation DES for ostial/midshaft lesions
in ULMCA are associated with favorable clinical outcomes, comparable to those
observed with ﬁrst generation DES.
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Background: Percutaneous coronary intervention (PCI) with drug eluting stent
(DES) implantation for left main coronary artery (LMCA) stenosis has been shown
to be a feasible and safe approach. However, optimal stenting technique is still
under discussion. Our goal is to evaluate safety and efﬁcacy of novel stenting
technique in LM distal lesions - intravascular ultrasound (IVUS) guided and op-
tical coherence tomography (OCT) optimized everolimus eluting platinum chro-
mium stent (SYNERGY) and bioresorbable coronary scaffold (ABSORB)
implantation.
Methods: 31 patient with distal LMCA are enrolled in ongoing study at Latvian
Center of Cardiology. All interventions were IVUS guided and OCT optimized.
Plaque modiﬁcation with cutting balloon before stenting was performed. SYNERGY
stent was implanted across the CX followed by ABSORB implantation at the proximal
CX. Procedure is ﬁnished with “kissing” post-dilation. 12-month angiographic, IVUS
and OCT follow-up is ongoing.
Results: All patients underwent the procedure due to stable angina, 25 (81%) of them
were males. Mean patient age was 6211 years, 26 (85%) of them were hypertonic
with dyslipidemia, 7 (23%) suffered from diabetes mellitus and were smokers. Mean
SYNTAX score 27,62,6. Synergy stent length implanted in LM-LAD was 236,53
mm, diameter 3,750,27mm. Mean Absorb scaffold length implanted in LM-LCX
was 163,10 mm, diameter 3,20,52 mm. Stenting technique: modiﬁed T stenting 10
cases, mini – Crush 21.There were no procedural complications. No major cardiac
adverse events occurred during hospitalization period and 30 day follow-up.
Conclusions: The current study demonstrates that novel LMCA stenting technique
using SYNERGY stent and ABSORB scaffold is safe and feasible. No seriousronary Lesions - Left Main B67









In - hospital Mortality, % (n) 15.4 (4) 34.2 (13) 0.04
In - hospital mortality, presenting with




In - hospital Stroke, % (n) 0 5.2 (2) -
In - hospital MI, % (n) 3.8 (1) 0 -
In - hospital MACCE, % (n) 15.4 (4) 34.2 (13) 0.04
30 - day mortality, % (n) 19.2 (5) 34.2 (13) 0.09
All-cause mortality, % (n) 38.5
(10)
39.5 (15) 0.46
SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PM www.jacctctabstracts2014.comprocedure-related complications were observed, hospital and 30 day clinical outcomes
appeared to be good. However, further evaluation is needed.
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Background: Percutaneous coronary intervention (PCI) of left main stem (LMS)
bifurcation is technically challenging and remains the focus of active research.
Currently, LMS bifurcation lesions in the presence of concomitant complex coronary
disease are preferentially treated with coronary artery bypass grafting (CABG).
However, LMS lesions with low Syntax scores have similar long term results with PCI
in comparison to CABG. There are deﬁciencies with current two stent bifurcation
techniques namely being ostial side branch (SB) stenosis. The role of dedicated
bifurcation stents is expanding in this arena. We describe the world’s ﬁrst series of
treating LMS bifurcation lesions using a 7-French compatible self-expanding, nitinol-
based, biolimus-coated, 4.0 x 9 mm AXXESS stent.
Methods: Patients with bifurcation lesions were prospectively enrolled in this study.
The AXXESS stent was deployed at the carina followed by drug eluting stent (DES)
deployment in the distal main vessel (MV) or SB if indicated. The procedures were
carried out by experienced operators with a special interest in bifurcation lesion
treatment.
Results: Ten patients were treated with the 4.0 x 9 mm AXXESS dedicated bifur-
cation stent in two high-volume centres in the UK. All patients had true bifurcation
lesions and 90% patients required an additional stent in either the distal MV, SB or
both. The device was successfully deployed in all cases which translated into a lesion
success rate of 100%. Following a six-month follow-up, no major adverse cardiac
events were observed.
Conclusions: Our data suggest that the 4.0 x 9 mm AXXESS dedicated bifurcation
stent can be safely used and successfully delivered to treat appropriate LMS bifur-
cation lesions with excellent peri-procedural success rates and six-month outcome
data. We anticipate presenting six-month follow-up data with optical frequency
domain imaging.
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Background: Current guidelines recommend percutaneous coronary intervention
(PCI) as the initial mode of revascularization for patients presenting with ST elevation
myocardial infarction (STEMI), however there is an ongoing debate on the mode of
revascularization for unprotected left main coronary artery (ULMCA) occlusion
presenting as STEMI with limited data available in this ﬁeld. Here we compare the
outcomes in patients undergoing PCI vs coronary artery bypass graft surgery (CABG)
for ULMCA occlusion STEMI.
Methods: We studied consecutive adults presenting with STEMI who had a critical
ULMCA occlusion (>50%) at The Cleveland Clinic between 9/2005 – 9/2013. They
were categorized on the basis of revascularization strategy – CABG, PCI or medical
treatment. Our primary endpoint was in-hospital mortality, 30-day mortality and all-
cause mortality.
Results: A total of 72 patients (mean age 67.25  14.14 years, 54.2% men) had
ULMCA occlusion with STEMI (LM alone 29.2%). Out of which, 26 patients (mean
age 66.2  17.1 years, 50% men, 46.2% LM alone, syntax score 25.96  7.63, 50% in
cardiogenic shock, EF 38.77  14.59%) underwent PCI, 38 patients (mean age 65.8 
12.1 years, 60.5% men, 23.7% LM alone, syntax score 26.92  8.76, 26.3% in
cardiogenic shock, EF 39  15.39 %) underwent CABG, while 8 patients had medical
therapy alone. In-hospital mortality rates were signiﬁcantly lower in patients who
underwent PCI as compared to CABG, 30 day mortality tended to be lower with PCI,
at a mean follow up of 2.92  2.71 years, all-cause mortality was similar in both
groups (Table 1).B68 JACC Vol 64/11/Suppl B jConclusions: Prognosis is guarded with high mortality irrespective of modality of
revascularization strategy in ULMCA occlusion presenting with STEMI. However, pa-
tients undergoing PCI had a signiﬁcant decrease in overall in-hospital mortality and tended
to show a decrease in in-hospital mortality for patients presenting with cardiogenic shock.
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Background: Limited data are available on the clinical outcomes of second-genera-
tion DES (2nd DES) in patients with unprotected left main coronary artery (LMCA)
lesions. We aimed to compare the clinical impacts of 2nd DES (everolimus-eluting
stent [EES] and biolimus-eluting stent [BES]) with those of sirolimus-eluting stent
(SES) and coronary artery bypass graft (CABG) in patients with unprotected LMCA
lesions and SYNTAX score 32.
Methods: We identiﬁed 333 patients with unprotected LMCA lesions and SYNTAX
score 32 between January 2003 and December 2012. The event rates of all-cause
death, cardiac death, target vessel revascularization (TVR), and major adverse cardiac
cerebrovascular events (MACCE: all-cause death, myocardial infarction [MI], stroke,
and TVR) and the composite endpoints including death, MI, and stroke were
compared between SES, EES/BES, and CABG. The exclusion criteria were previous
PCI/CABG and acute MI within 24 hours from the onset.
Results: Of the 333 patients, 111 underwent implantation of SES, 58 EES/BES (EES,
18 and BES, 40), and 164 CABG. No signiﬁcant differences existed in baseline
characteristics. Cardiac death did not signiﬁcantly differ between the 3 groups. At 2
years, all event rates of CABG except cardiac death were signiﬁcantly lower than
those of SES and not signiﬁcantly different from those of EES/BES. Moreover, TVR
and MACCE of EES/BES were signiﬁcantly lower than those of SES
Conclusions: In patients with unprotected LMCA lesions and SYNTAX score 32,
the clinical outcomes of EES/BES were better than those of SES and not signiﬁcantly
different from those of CABG.September 13–17, 2014 j TCT Abstracts/Coronary Lesions - Left Main
